Clinical Trial Update: Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone. [Phase 2]

View source ↗

Summary

Phase 2 exploratory trial evaluating Inetetamab (Cipterbin) + PD-1 inhibitor with Utidelone in HER2-positive metastatic breast cancer after multi-line therapy f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Inetetamab (Cipterbin) (Inetetamab)
• PD-1 inhibitor
• Utidelone (utidelone)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: HER2 Positive Metastatic Breast Cancer | Phase 2 | Status: UNKNOWN